# Discovery of Anticancer Agents of Diverse Natural Origin

> **NIH NIH P01** · OHIO STATE UNIVERSITY · 2021 · $154,802

## Abstract

OVERALL P01 PROJECT SUMMARY
In this Program Project renewal application, the applicant group is representative of three primary institutions,
The Ohio State University (OSU), the University of Illinois at Chicago (UIC), and the University of North Carolina
at Greensboro (UNCG). The participants have combined their vast experience in the isolation, structure
elucidation, and biological evaluation of natural products, to the development of a consolidated, integrated
program for the discovery of novel anticancer agents of diverse origin for development as cancer
chemotherapeutic agents. Plant materials to be studied in Project 1 (OSU) will be collected by established
botanists located in tropical countries with the assistance of the NAPRALERT database (Project 2; UIC), and
lichens and their fungal associates (Project 1), cyanobacteria (Project 2) and filamentous fungi (Project 3;
UNCG) will also be accessed. Organisms acquired will be extracted and evaluated in a diverse battery of relevant
mechanism-based, cell-based, and tumor-growth related assays currently operational at OSU (Project 1), UIC
(Core 1), Columbia University (through Project 3), and via other external collaborators (through Core A at OSU).
Dereplication of known active compounds will be accomplished at OSU, UIC, and UNCG using computerized
literature surveys and LC-MS coupled to bioassays. Bioassay-directed fractionation will be employed in Projects
1-3 for the elucidation of the active principles. Lead development of active natural products via medicinal
chemistry and pharmacokinetics-related studies will be conducted at OSU (Core 2), facilitated by the OSU
Biostatistics group (Core A). Novel, active compounds thus discovered will be further evaluated in our panel of
in vitro and in vivo bioassays (Projects 1 and 3, Core A, and some external collaborators). Group decisions will
be made regarding the further development of agents for potential use as anticancer agents. The more advanced
stages of biological and toxicological testing will be aided through consultation with the Drug Discovery Institute
of the OSU Comprehensive Cancer Center (through Core A). The Consortium will work with the involvement of
the NCI Program Official in the discovery process, and plans to hold regular meetings of key scientific personnel
(inclusive of our External and OSU Internal Scientific Advisory Boards) to enhance communication and decision-
making processes, to be organized by Core A. Excellent facilities for the isolation, structure determination,
chemical modification, synthesis, and in vitro and in vivo biological evaluation, and overall project data
management are available. The overarching goal of this P01 is to identify lead compounds that ultimately have
therapeutic value for the treatment of cancer.

## Key facts

- **NIH application ID:** 10380980
- **Project number:** 3P01CA125066-12S1
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** Alan Douglas Kinghorn
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $154,802
- **Award type:** 3
- **Project period:** 2007-07-01 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10380980

## Citation

> US National Institutes of Health, RePORTER application 10380980, Discovery of Anticancer Agents of Diverse Natural Origin (3P01CA125066-12S1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10380980. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*